アルツハイマー病: 病理生物学と治療策の最新報告

Justin M Long¹, David M Holtzman¹

¹Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.

Cell

|October 1, 2019

まとめ

アルツハイマー病 (AD) はアミロイドプラークやタウ・タングルを超えて複雑な病理学を含んでいます. 研究により新しい細胞のプロセスが明らかになったが,ADの治療には効果的な治療法が必要である.

科学分野:

神経学
神経科学
病理生物学

背景:

アルツハイマー病 (AD) の特徴は,アミロイド斑と神経線維の絡みである.
最近の発見はADの病理生物学に関与する他の重要な細胞および分子プロセスを明らかにしています
現在のADの治療法は病気を変化させないし臨床試験では成功は限られている.

研究の目的:

アルツハイマー病の病理生物学の理解における最近の進歩をレビューする.
アルツハイマー病の治療戦略と臨床試験について
病気を改変する治療法の開発の機会を特定する.

主な方法:

AD病理生物学における最近の基本的な発見に関する文献レビュー.
現在の治療戦略と第3相臨床試験の結果の分析
新しい治療目標のための新興の研究の探索

主要な成果:

アルツハイマー病の病理生物学は以前より複雑で複数の細胞と分子経路が関与しています
広範な研究にも関わらず,ADの最終的な治療法はありません.
多くの臨床試験では有意な効果が示されず新しいアプローチの必要性を強調しています

結論:

アルツハイマー病の複雑な病理生物学を総合的に理解することは効果的な治療法の開発に不可欠です
アルツハイマー病の将来の治療戦略は,より幅広い病理学的メカニズムを考慮する必要があります.
新しい標的とアプローチに関する研究が継続されることは,AD治療の進歩に不可欠です.

さらに関連する動画

06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.7K

09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.7K

関連する概念動画

01:26

Alzheimer's Disease: Overview

1.6K

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

1.6K

01:22

Alzheimer's Disease: Treatment

827

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

827

01:15

Parkinson's Disease: Overview

1.8K

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

1.8K

01:24

Parkinson's Disease: Treatment

995

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

995

01:30

Dementia

526

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....

526

03:03

Amyloid Fibrils

11.7K

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...